Relmada Therapeutics Revenue and Competitors

Location

N/A

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • Relmada Therapeutics's estimated annual revenue is currently $5.4M per year.(i)
  • Relmada Therapeutics's estimated revenue per employee is $150,750
  • Relmada Therapeutics's current valuation is $550.6M. (January 2022)

Employee Data

  • Relmada Therapeutics has 36 Employees.(i)
  • Relmada Therapeutics grew their employee count by -14% last year.

Relmada Therapeutics's People

NameTitleEmail/Phone
1
CEOReveal Email/Phone
2
Chief Accounting & Compliance OfficerReveal Email/Phone
3
Head CommercialReveal Email/Phone
4
SVP OperationsReveal Email/Phone
5
EVP Brand ExperienceReveal Email/Phone
6
VP MarketingReveal Email/Phone
7
Senior Director, Clinical ResearchReveal Email/Phone
8
Chief Medical OfficerReveal Email/Phone
9
Chief Financial OfficerReveal Email/Phone
10
Chief Clinical OfficerReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$12.3M617%N/AN/A
#2
$354.3M461-2%$567.1MN/A
#3
$377.1M1876-1%N/AN/A
#4
$7.8M398%N/AN/A
#5
$5.4M270%N/AN/A
#6
$45M2246%N/AN/A
#7
$6.8M34-82%N/AN/A
#8
$9.2M4612%N/AN/A
#9
N/A69446%N/AN/A
#10
$15.5M775%N/AN/A
Add Company

What Is Relmada Therapeutics?

Relmada Therapeutics (OTCQB: RLMD) is a clinical-stage, publicly traded specialty pharmaceutical company developing novel versions of proven drug products together with new chemical entities that potentially address areas of high unmet medical need in the treatment of chronic pain. Relmada has a diversified portfolio of four lead products at various stages of development including d-Methadone (REL-1017) its N-methyl-D-aspartate (NMDA) receptor antagonist for neuropathic pain; topical mepivacaine (REL-1021), its orphan drug designated topical formulation of the local anesthetic mepivacaine; oral buprenorphine (REL-1028) its oral dosage form of the opioid analgesic buprenorphine; and LevoCap ER (REL-1015), its abuse resistant, sustained release dosage form of the opioid analgesic levorphanol. Relmada's product development efforts are guided by the internationally recognized scientific expertise of our research team. Relmada's approach is expected to reduce clinical development risks and costs while potentially delivering valuable products in areas of high unmet medical needs. For more information, please visit our website at: www.relmada.com

keywords:N/A

N/A

Total Funding

36

Number of Employees

$5.4M

Revenue (est)

-14%

Employee Growth %

$550.6M

Valuation

N/A

Accelerator

Relmada Therapeutics News

2022-04-20 - Relmada Therapeutics, Inc. (NASDAQ:RLMD) Short Interest ...

Get Relmada Therapeutics alerts: RLMD traded up $0.33 during trading on Tuesday, reaching $26.00. The stock had a trading volume of 4,275 shares...

2022-04-06 - Relmada Therapeutics files for mixed shelf offering

Relmada Therapeutics (NASDAQ:RLMD) has filed for a mixed shelf offering. The amount has yet to be determined.

2022-03-22 - Relmada Therapeutics Provides Corporate Update and ...

Relmada Therapeutics is a late-stage biotechnology company addressing diseases of the central nervous system (CNS), with a focus on major...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$15M36-10%$1.4M
#2
$4M36-28%$31.5M
#3
$3.6M360%$65.4M
#4
$3.6M36-5%$7.5M
#5
$4.2M36N/AN/A